Diven MA, Tshering L, Ma X, Hu JC, Barbieri C, McClure T, et al. Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2024;7:e2429760.
Google Scholar
Eraky A, Tillu N, Ben-David R, Hug B, Jodka H, Agarwal Y, et al. Diagnostic Accuracy of [(18)F]-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy: Is Pelvic Lymph Node Dissection Still Necessary? J Urol. 2025;214:365–73.
Google Scholar
Flammia RS, Hoeh B, Chierigo F, Hohenhorst L, Sorce G, Tian Z, et al. Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registries. Curr Urol. 2022;16:191–6.
Google Scholar
Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Eur Urol Oncol. 2022;5:1–17.
Google Scholar
Song D, Malshy K, Messing EM, Joseph JV, Bandari J. Excluding PLND in favourable intermediate-risk prostate cancer: a PSMA-PET-directed perspective. Nature Rev Urol. 2025;13:6534.
Orsini A, Cicchetti R, Digiacomo A, De Archangelis R, Basconi M, Litterio G, et al. Avoiding pelvic lymph node dissection in intermediate-risk prostate cancer with negative PSMA PET: a step toward personalized surgery. Minerva Urol Nephrol. 2025;77:422–4.
Google Scholar
Zattoni F, Carletti F, Reitano G, Novara G, Dal Moro F. PSMA PET vs. surgery: redefining lymph node staging in prostate cancer. Minerva Urol Nephrol. 2024;76:785–7.
Google Scholar
Morizane S, Takenaka A. Current status and therapeutic value of extended pelvic lymph node dissection during radical prostatectomy for prostate cancer. Prostate Int. 2024;12:117–27.
Google Scholar
Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, et al. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D’Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. J Urol. 2020;203:338–43.
Google Scholar
Carll J, Shi W, Perera M, Lawrentschuk N, Chengodu T, Woon D. Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer. BJU Int. 2025;136:800–4.
Google Scholar
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.
Google Scholar
Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, et al. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2023;84:36–48.
Google Scholar
Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, et al. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. Eur Urol Oncol. 2022;5:544–52.
Google Scholar
Kopp D, Kopp J, Bernhardt E, Manka L, Beck A, Gerullis H, et al. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer. Urol Int. 2022;106:56–62.
Google Scholar
Bauckneht M, Checcucci E, Lanfranchi F, Cisero E, Rizzo A, Scuderi S, et al. The added value of PSMA PET to nomograms in identifying optimal candidates for extended pelvic lymph node dissection in intermediate-risk prostate cancer patients. Minerva Urol Nephrol. 2025;77:639–46.
Google Scholar
Incesu RB, Preisser F, Nohe F, Maurer T, Graefen M, Tilki D. Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer. Prostate Cancer Prostatic Diseases 2025;28:874–8.
Evangelista L, Guglielmo P, Giacoppo G, Setti L, Aricò D, Muraglia L, et al. The Evaluation of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Initial Staging in Intermediate-Risk Prostate Cancer Patients: A Retrospective Multicenter Analysis. Diagnostics 2024;14:2751.
Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61:480–7.
Google Scholar
Salameh JP, Bossuyt PM, McGrath TA, Thombs BD, Hyde CJ, Macaskill P, et al. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020;370:m2632.
Google Scholar
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.
Google Scholar
Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, et al. 68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy. World J Urol. 2020;38:3085–90.
Google Scholar
Özman O, Veerman H, Contieri R, Droghetti M, Donswijk ML, Hagens MJ, et al. Staging Accuracy and Prognostic Value of Prostate-Specific Membrane Antigen PET/CT Strongly Depends on Lymph Node Tumor Burden. J Clin Med. 2024;13:6534.
Van Bergen TD, Braat A, Hermsen R, Heetman JG, Wever L, Lavalaye J, et al. External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:3744–56.
Google Scholar
Esen B, Seymen H, Armutlu A, Koseoglu E, Aykanat IC, Zoroğlu H, et al. Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate-Risk Prostate Cancer Patients With Node-Negative PSMA PET. Prostate. 2025;85:777–83.
Google Scholar
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, et al. Diagnostic Performance and Safety of Positron Emission Tomography with (18)F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). Eur Urol. 2023;84:361–70.
Google Scholar
Ingvar J, Hvittfeldt E, Trägårdh E, Simoulis A, Bjartell A. Assessing the accuracy of [(18)F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. EJNMMI Res. 2022;12:48.
Google Scholar
Dekalo S, Kuten J, Campbell J, Mintz I, Bar-Yosef Y, Keizman D, et al. 68)Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer. Can Urol Assoc J. 2022;16:E381–5.
Google Scholar
Frumer M, Milk N, Rinott Mizrahi G, Bistritzky S, Sternberg I, Leibovitch I, et al. A comparison between (68)Ga-labeled prostate-specific membrane antigen-PET/CT and multiparametric MRI for excluding regional metastases prior to radical prostatectomy. Abdom Radiol. 2020;45:4194–201.
Google Scholar
Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, et al. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with (68)Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. J Urol. 2019;201:815–20.
Google Scholar
Incesu RB, Preisser F, Pompe RS, Nohe F, Mandel P, Maurer T, et al. Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy. Eur Urol Focus 2025;11:582–7.
Kim TH, Woo S. How Systematic Review Can Shape Clinical Practice in Radiology. AJR Am J Roentgenol. 2024;222:e2329603.
Google Scholar
Mazzone E, Cannoletta D, Quarta L, Chen DC, Thomson A, Barletta F, et al. A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment. Eur Urol. 2025;87:654–71.
Google Scholar
Bonaddio J, Carll J, Eapen R, Sathianathen N, Lawrentschuk N. The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer. BJU Int. 2025;137:49–57.
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86:148–63.
Google Scholar
Bonaddio J, Carll J, Eapen R, Sathianathen N, Lawrentschuk N. The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer. BJU Int. 2026;137:49–57.
Google Scholar
Hartwieg BF, Maurer T, Kniep C, Mandel P, Wenzel M, Falkenbach F, et al. Use of staging in intermediate-risk prostate cancer: A real-world data analysis. Urol Oncol. 2026;44:71.e71–71.e77.
Google Scholar
Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001;91:66–73.
Google Scholar
Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004;172:2252–5.
Google Scholar
Meijer D, Ettema RH, van Leeuwen PJ, van der Kwast TH, van der Poel HG, Donswijk ML, et al. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer. BJU Int. 2023;131:330–8.
Google Scholar
Pozin J, Bhandari M, Valle L, Nickols NG, Kishan AU, Kamran SC, et al. The Evolving Management of Radiorecurrent Prostate Cancer. Semin Radiat Oncol. 2025;35:450–62.
Google Scholar
Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399:1886–901.
Google Scholar
Fink CA, Wegener D, Sauer LD, Lentz-Hommertgen A, Liermann J, Müller AC, et al. Pelvic Irradiation for Node-Positive Prostate Cancer After Prostatectomy: Long-Term Results of the Prospective PLATIN-4 and PLATIN-5 Trials. Int J Radiat Oncol Biol Phys. 2024;118:1011–7.
Google Scholar
Clinckaert A, Callens K, Cooreman A, Bijnens A, Moris L, Van Calster C, et al. The Prevalence of Lower Limb and Genital Lymphedema after Prostate Cancer Treatment: A Systematic Review. Cancers 2022;14:5667.
Peilleron N, Seigneurin A, Herault C, Verry C, Bolla M, Rambeaud JJ, et al. External evaluation of the Briganti nomogram to predict lymph node metastases in intermediate-risk prostate cancer patients. World J Urol. 2021;39:1489–97.
Google Scholar
Kuperus JM, Tobert CM, Semerjian AM, Qi J, Lane BR. Pelvic Lymph Node Dissection at Radical Prostatectomy for Intermediate Risk Prostate Cancer: Assessing Utility and Nodal Metastases Within a Statewide Quality Improvement Consortium. Urology. 2022;165:227–36.
Google Scholar
Gofrit ON, Orevi M, Ben-Haim S, Meuman T, Duvdevani M, Hidas G, et al. The relevance of nomograms for prediction of pelvic lymph node metastases in the prostate-specific membrane antigen (PSMA)-PET/CT era. Curr Urol. 2025;19:353–6.
Google Scholar
